tbuckley/cabot-search huggingface dataset:
Leadership Program Award Recipients
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Government Issues Guidelines to Stem Rising Tuberculosis Rates in Prisons
Authors: Andrew Skolnick
Journal: JAMA (1989)

IN RESPONSE to the alarming increase of tuberculosis (TB) rates in many of the nation's prisons, the Centers for Disease Control (CDC), Atlanta, Ga, has published recommendations for the prevention and control of TB among prison populations (<i>MMWR</i>. 1989;38:313-320,325 and this issue.) This is the first time the CDC has issued guidelines regarding health care in correctional institutions. Speaking at the 13th National Conference on Correctional Health Care in Chicago, Ill, John J. Seggerson, Jr, MD, chief, Program Services Branch of the CDC's Division of Tuberculosis Control, explained the epidemiologic reasons for the recommendations. <h3>Eleven Known Outbreaks</h3> Over the last few years, increasing rates of TB in certain demographic pockets have brought the decline in the incidence of TB in the United States to a halt. Since 1985, 11 known TB outbreaks have occurred in prisons in eight states, Seggerson says. One such outbreak was described at the conference by
Of Little Patients
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Food and Drug Administration: how 'those regulations' came to be
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Estimating Xenobiotic Half-Lives in Humans from Rat Data: Influence of log P
Authors: Jeffrey G. Sarver, Donald White, Paul Erhardt, Kenneth Bachmann
Journal: Environmental Health Perspectives (1997)

The nature of empirical allometric expressions relating dispositional and kinetic parameters for a given xenobiotic across multiple mammalian species is well known. It has also been demonstrated that a simple allometric relationship may be used to predict kinetic parameters for humans based merely on data for multiple xenobiotics from rats. We decided to explore reasons for the variance in the data arising from the latter method. We were particularly interested in learning whether any physicochemical characteristics of xenobiotics might account for outlying data points (i.e., poor prediction of human half-life from rat half-life). We have explored the influence of lipid solubility as reflected by a xenobiotic's log P value because adipose tissue comprises a significantly larger percentage of total body weight in humans than in rats. We used half-life data from the literature for 127 xenobiotics. A data subset of 102 xenobiotics for which we were able to find estimates of log P values, including several with extremely large log P values, was also analyzed. First and second order models, including and excluding log P, were compared. The simplest of these models can be recast as the familiar allometric relationship having the form Y = a(Xb). The remaining models can be seen as extensions of this relationship. Our results suggest that incorporation of log P into the prediction of xenobiotic half-life in humans from rat half-life data is important only for xenobiotics with extremely large log P values such as dioxins and polychlorinated biphenyls. Moreover, a second order model in logarithm of rat half-life accommodates all data points very well, without specifically accounting for log P values.
Cadaver Transplants 'Encouraging'
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).
Authors: Myung-Ju Ahn, Fabrice Barlesi, Enriqueta Felip, Edward B. Garon, Claudio Marcelo Martin, Tony S. K. Mok, Everett E. Vokes, Laureen S. Ojalvo, Andre Koenig, Isabelle Dussault, Luis G. Paz-Ares
Journal: Journal of Clinical Oncology (2019)

TPS127 Background: Transforming growth factor β (TGF- β) promotes tumor progression via immune- and non–immune-related processes. M7824 is an innovative first-in-class bifunctional fusion protein composed of 2 extracellular domains of TGF-βRII (a TGF-β “trap”) fused to a human IgG1 monoclonal antibody against PD-L1. Targeting these independent and complementary pathways may restore and enhance antitumor responses. An expansion cohort of the study of patients with advanced NSCLC (n=80) treated with M7824 in the second-line setting presented at ESMO 2018 showed an objective response rate of 86% in the subgroup with high PD-L1 tumor expression at the recommended phase 2 dose (1200 mg intravenously [IV] every 2 weeks [Q2W]). Observed data support the hypothesis that M7824 may be superior to other PD-(L)1 inhibitors, including pembrolizumab, for the treatment of NSCLC. Based on the promising antitumor activity and manageable safety profile, this study will evaluate M7824 treatment in patients with advanced NSCLC in the 1L setting. Methods: Here we present a global, randomized trial comparing M7824 vs pembrolizumab in the 1L treatment of patients with metastatic NSCLC with high PD-L1 expression levels. Patients in this study must have a histologically confirmed diagnosis of advanced NSCLC with high PD-L1 expression on tumor cells (defined as either ≥80% by the Dako 73-10 pharmDx kit or ≥50% by the Dako 22C3 pharmDx kit since both assays are expected to select a similar patient population at their respective cut-offs). ECOG performance status must be 0 or 1. Patients must not have received prior systemic treatment for advanced NSCLC. Patients with tumors with actionable mutations (for which targeted therapy is locally approved) are not eligible. Patients will receive 1200 mg Q2W or pembrolizumab 200 mg Q3W as an IV infusion until confirmed disease progression, unacceptable toxicity, or trial withdrawal. Dual primary endpoints are progression-free survival and best overall response; key secondary endpoints include overall survival, duration of response, and safety. Estimated enrollment is 300 patients. Clinical trial information: NCT02517398, NCT03631706 .
The Clinical Significance Of Specific Antibody Deficiency (SAD) Severity In Chronic Rhinosinusitis (CRS)
Authors: Anjeni Keswani, Neha Mehrotra, Angelica Manzur, Rakesh Chandra, David Conley, Bruce K. Tan, Leslie C. Grammer, Robert C. Kern, Robert P. Schleimer, Anju T. Peters
Journal: Journal of Allergy and Clinical Immunology (2014)
Cellular And Molecular Mechanisms Of Allograft Rejection
Authors: R. Colvin
Journal: Annual Review of Medicine (1990)

CD40 is a cell-surface member of the TNF (tumor necrosis factor) receptor superfamily. Upon activation, CD40 can license dendritic cells to promote antitumor T cell activation and re-educate macrophages to destroy tumor stroma. Numerous agonist CD40 ...Read More
Influenza pandemics in perspective
Authors: E. D. Kilbourne
Journal: JAMA (1977)

IT IS NOW nine months<sup>*</sup>since the recognition of an influenza epidemic caused by swine influenza virus in military personnel at Fort Dix, NJ. The gestation period of an influenza pandemic is unknown, but in this case, long labor has preceded the delivery. Whatever else may be said of our unprecedented national effort for the amelioration of a pandemic for the first time in history, we now have an overwhelming balance of vaccine doses available to manifest cases of disease—about 150 million to zero (sporadic cases occurred subsequently in January). The basis of the decision to act aggressively against swine influenza has been cited more frequently in the lay press than in professional journals. In brief, the decision rested on (1) expectation of the emergence of a new major virus variant within the next few years on the basis of decennial periodicity of pandemics,<sup>1</sup>(2) the unprecedented observation of
Instructions for Authors
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
"Safety of formoterol Turbuhaler® at cumulative dose of 90 µg in patients with acute bronchial obstruction”. J. Malolepszy, G. Böszörményi Nagy, O. Selroos, P. Larsson, R. Brander.<i>Eur Respir J</i>2000; 18: 928–934
Journal: European Respiratory Journal (2002)

on page 928.The corrected paragraph is reproduced in full below.Oxis1 Turbuhaler1 (90 mg) was at least as safe and well tolerated as terbutaline (10 mg) in patients with acute bronchoconstriction.
Correction
Journal: BMJ (1965)

We publish below a selection of questions and answers of general interest.Magnesium Oxide Fume Q.-Is the inhalation of dust particles of magnesium oxide harmful, and what can be done to guard against it?A.-The absorption of magnesium from industrial exposure is not accompanied by systemic effects, and there is no evidence that the inhalation of magnesium oxide dust par- ticles leads to lung injury.On the other hand, the inhalation of magnesium oxide fume in sufficient quantity will produce metal-fume fever.Protection is best pro- vided by the application of an efficient local exhaust system, and, if this is not sufficient, by supplying the exposed employees with an approved respirator.
Widened mediastinum after a penetrating injury of the chest
Authors: J. M. Weiss
Journal: JAMA (1975)

<h3>History</h3> A 7-year-old boy was transferred to the hospital from a smaller community hospital three hours after walking through a plate glass window and sustaining a penetrating injury to the left anterior chest wall. A long glass fragment had been extracted, apparently intact, at the first hospital. The patient, on admission, showed evidence of diminished heart sounds and decreased breath sounds over the left hemithorax. The hemoglobin value was 8.3 gm/100 ml. A posteroanterior chest roentgenogram (Fig 1) was obtained on admission and an aortogram (Fig 2) done shortly thereafter. <h3>Diagnosis</h3> Laceration of the left internal mammary artery. <h3>Comment</h3> The admission chest roentgenogram (Fig 1) shows a widened mediastinum and left pleural effusion. The tentative diagnosis at that time was mediastinal hematoma and hemothorax on the left caused by penetrating injury of the aorta. However, as seen in Fig 2, the aorta is intact. The right internal mammary artery is
Babesiosis—Connecticut
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply
Authors: J.C.J.M. Veraart, K. Hamulyak, H.A.M. Neumann, J. Engelen
Journal: British Journal of Dermatology (1994)

Journal Article Reply Get access J.C.J.M. Veraart, J.C.J.M. Veraart Department of Dermatology, Academisch Ziekenhuis, Maastricht, the Netherlands Search for other works by this author on: Oxford Academic Google Scholar K. Hamulyak, K. Hamulyak Department of Haematology, Academisch Ziekenhuis, Maastricht, the Netherlands Search for other works by this author on: Oxford Academic Google Scholar H.A.M. Neumann, H.A.M. Neumann Department of Dermatology, Academisch Ziekenhuis, Maastricht, the Netherlands Search for other works by this author on: Oxford Academic Google Scholar J. Engelen J. Engelen Department of Clinical Genetics, Academisch Ziekenhuis, Maastricht, the Netherlands Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 131, Issue 5, 1 November 1994, Pages 738–739, https://doi.org/10.1111/j.1365-2133.1994.tb04999.x Published: 01 November 1994
Review of Neural Tube Defects: Risk Factors in Parental Occupation and the Environment
Authors: Birgitte M. Blatter, Marjolijn van der Star, Nel Roeleveld
Journal: Environmental Health Perspectives (1994)

We conducted a study of published work to evaluate the evidence for the hypothesis that environmental exposure and parental occupation are risk factors for neural tube defects. As other risk factors such as maternal illnesses, medication, and dietary factors have been reviewed before, this review only summarizes this information. In studies concerning environmental pollution, only a few weak associations were found. It appears that specific studies on the topic of parental occupation and neural tube defects are scarce. Therefore, studies on broader malformation categories, such as central nervous system defects, were also taken into account. Both maternal and paternal occupation seem to be associated with the occurrence of neural tube defects. However, results are not always consistent with each other, and relevant recommendations concerning prevention thus cannot be given before more studies with larger populations are conducted to confirm or refute the findings reviewed.
Intergalactic Taco
Authors: THOMAS P. BERESFORD
Journal: Annals of Internal Medicine (1985)

Ad Libitum1 September 1985Intergalactic TacoTHOMAS P. BERESFORD, M.D.THOMAS P. BERESFORD, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-103-3-459 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe cafeteria was the best Mexican restaurant in town. Steele was always fond of saying so. That was one of the benefits of working in San Jose. The Mexican restaurant, I mean. Not that I want to cast any aspersions on Steele. He was a genuine sort, treated his patients with respect and was available more than any other OB-GYN man I've ever known. And that's saying a lot because most of them work around the clock. They flock together for the preservation of sanity. Babies drop in without knowledge of the cocktail hour. Steele was the chief of the... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Memphis, Tennessee PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 September 1985Volume 103, Issue 3Page: 459-459KeywordsObstetrics and gynecology Issue Published: 1 September 1985 PDF DownloadLoading ...
Detection of West Nile Virus in Blood Donations—Puerto Rico, 2007
Journal: JAMA (2008)

In the United States, West Nile virus (WNV) was first detected in humans in 1999; it subsequently spread to countries of Central and South America and the Caribbean. WNV is a mosquito-borne virus that produces potentially serious clinical disease, particularly among persons aged > or =50 years. Transmission by routes other than mosquito bites, including blood transfusion, transplacental infection, organ transplant, and possibly breast milk, also have been reported. On July 19, 2007, the American Red Cross in Puerto Rico notified the Puerto Rico Department of Health (PRDH) of three persons whose blood donations were positive for WNV by nucleic acid-amplification test (NAT) screening. These three donors had the first confirmed human WNV infections detected in Puerto Rico. In response, PRDH and CDC conducted in-depth interviews of the blood donors. This report describes these human infections and other recent surveillance for transmission of WNV in Puerto Rico. Detection of WNV infections in human blood donors indicates that heightened clinician awareness, ongoing surveillance, and educational activities are needed to monitor and assess the public health threat posed by WNV in Puerto Rico.